--- type: "firecrawl-provider" description: "ChEMBL, EMBL-EBI's open database of bioactive drug-like molecules (www.ebi.ac.uk/chembl), through its keyless JSON web services: molecule search by name or synonym and molecule records (structure, properties, max phase, synonyms, mechanisms of action), drug indications with EFO/MeSH terms and phases, drug targets with UniProt accessions, and bioactivity measurements (IC50, Ki, Kd, EC50, pChEMBL) by molecule and/or target. Data CC BY-SA 3.0 (attribution, share-alike); every output carries the licence and ChEMBL release." use_when: "ChEMBL, EMBL-EBI's open database of bioactive drug-like molecules (www.ebi.ac.uk/chembl), through its keyless JSON web services: molecule search by name or synonym and molecule records (structure, properties, max phase, synonyms, mechanisms of action), drug indications with EFO/MeSH terms and phases, drug targets with UniProt accessions, and bioactivity measurements (IC50, Ki, Kd, EC50, pChEMBL) by molecule and/or target. Data CC BY-SA 3.0 (attribution, share-alike); every output carries the licence and ChEMBL release.\n\nChEMBL, EMBL-EBI's open database of bioactive drug-like molecules (www.ebi.ac.uk/chembl), through its keyless JSON web services: molecule search by name or synonym and molecule records (structure, properties, max phase, synonyms, mechanisms of action), drug indications with EFO/MeSH terms and phases, drug targets with UniProt accessions, and bioactivity measurements (IC50, Ki, Kd, EC50, pChEMBL) by molecule and/or target. Data CC BY-SA 3.0 (attribution, share-alike); every output carries the licence and ChEMBL release.\n\nChEMBL, EMBL-EBI's open database of bioactive drug-like molecules (www.ebi.ac.uk/chembl), through its keyless JSON web services: molecule search by name or synonym and molecule records (structure, properties, max phase, synonyms, mechanisms of action), drug indications with EFO/MeSH terms and phases, drug targets with UniProt accessions, and bioactivity measurements (IC50, Ki, Kd, EC50, pChEMBL) by molecule and/or target. Data CC BY-SA 3.0 (attribution, share-alike); every output carries the licence and ChEMBL release." categories: "Health" capabilities: 6 credits_per_call: 5 --- # ChEMBL on Firecrawl Alexandria ChEMBL, EMBL-EBI's open database of bioactive drug-like molecules (www.ebi.ac.uk/chembl), through its keyless JSON web services: molecule search by name or synonym and molecule records (structure, properties, max phase, synonyms, mechanisms of action), drug indications with EFO/MeSH terms and phases, drug targets with UniProt accessions, and bioactivity measurements (IC50, Ki, Kd, EC50, pChEMBL) by molecule and/or target. Data CC BY-SA 3.0 (attribution, share-alike); every output carries the licence and ChEMBL release. - Categories: Health - Category index: [Health category](https://firecrawl.dev/alexandria/agents/categories/health) - Provider key: `ebi-ac-uk` - Access: Firecrawl credits - Cost: 5 credits per call ## More - [Human guide](https://firecrawl.dev/app/alexandria/ebi-ac-uk) - [OpenAPI spec](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/openapi.json) ## Capabilities - [Drug indications](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/molecules/drug_indications): Drug indications ChEMBL records for a molecule and all forms of its parent compound: EFO and MeSH disease terms, the highest phase reached for each indication, and references (ClinicalTrials.gov, DailyMed, FDA, EMA, ATC). Most advanced phase first; min_phase 4 keeps approved indications. Paginated. Data CC BY-SA 3.0 with attribution. - [Get molecule](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/molecules/get_molecule): One ChEMBL molecule by ChEMBL ID, standard InChIKey or ChEMBL compound URL: preferred name, type, max phase, first approval, availability, drug flags (oral, black box warning, first in class, ...), ATC codes, structure (canonical SMILES, InChI, InChIKey), calculated properties (MW, ALogP, PSA, HBA/HBD, rotatable bonds, Ro5 violations, QED), biotherapeutic sequence and HELM for antibodies and proteins, typed synonyms, cross-references, and the mechanisms of action of its parent compound with targets and references. Data CC BY-SA 3.0 with attribution; ChEMBL computes the properties with RDKit and ChemAxon software and asks that they not be extracted in isolation to train models that replicate the commercial calculations. - [Search molecules](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/molecules/search_molecules): Search ChEMBL molecules by name, synonym, trade name or research code (imatinib, Gleevec, STI571, aspirin), ranked by relevance. Each hit has the ChEMBL ID, preferred name, type, max development phase, first approval year, parent compound, canonical SMILES, standard InChIKey, formula, molecular weight and synonyms. Optional min_phase keeps clinical or approved drugs (4). Paginated; ChEMBL search stops at 10,000 hits. Data CC BY-SA 3.0 with attribution. - [Get target](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/targets/get_target): One ChEMBL target by ChEMBL ID or ChEMBL target URL: name, type, organism, taxonomy ID and every component with its UniProt accession, gene symbol and synonyms (gene names, UniProt names, EC numbers); include_xrefs adds each component's PDB, Reactome, GO, InterPro, Pfam and other cross-references. Data CC BY-SA 3.0 with attribution. - [Search targets](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/targets/search_targets): Find ChEMBL drug targets by free text (gene symbol, protein name, e.g. EGFR, cyclooxygenase) or by exact UniProt accession, optionally restricted to an organism (exact name, e.g. Homo sapiens) and target type (SINGLE PROTEIN, PROTEIN COMPLEX, ...). Each target has its ChEMBL ID, name, type, organism, taxonomy ID and components with UniProt accessions and gene symbols. Paginated. Data CC BY-SA 3.0 with attribution. - [List activities](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/activities/list_activities): Bioactivity measurements from ChEMBL for a molecule, a parent compound with all its salt forms, a target, or a molecule-target pair: standard type (IC50, Ki, Kd, EC50, ...), relation, value and units, pChEMBL value, assay (ChEMBL ID, type, description, variant mutation), target, ligand efficiency, data-validity flags and source document. Filters: standard_type, min_pchembl, assay_type, target_organism. sort potency returns the most potent first (rows with a pChEMBL value only). Paginated. Data CC BY-SA 3.0 with attribution. ## 1. Choose this provider when ChEMBL, EMBL-EBI's open database of bioactive drug-like molecules (www.ebi.ac.uk/chembl), through its keyless JSON web services: molecule search by name or synonym and molecule records (structure, properties, max phase, synonyms, mechanisms of action), drug indications with EFO/MeSH terms and phases, drug targets with UniProt accessions, and bioactivity measurements (IC50, Ki, Kd, EC50, pChEMBL) by molecule and/or target. Data CC BY-SA 3.0 (attribution, share-alike); every output carries the licence and ChEMBL release. ChEMBL, EMBL-EBI's open database of bioactive drug-like molecules (www.ebi.ac.uk/chembl), through its keyless JSON web services: molecule search by name or synonym and molecule records (structure, properties, max phase, synonyms, mechanisms of action), drug indications with EFO/MeSH terms and phases, drug targets with UniProt accessions, and bioactivity measurements (IC50, Ki, Kd, EC50, pChEMBL) by molecule and/or target. Data CC BY-SA 3.0 (attribution, share-alike); every output carries the licence and ChEMBL release. ChEMBL, EMBL-EBI's open database of bioactive drug-like molecules (www.ebi.ac.uk/chembl), through its keyless JSON web services: molecule search by name or synonym and molecule records (structure, properties, max phase, synonyms, mechanisms of action), drug indications with EFO/MeSH terms and phases, drug targets with UniProt accessions, and bioactivity measurements (IC50, Ki, Kd, EC50, pChEMBL) by molecule and/or target. Data CC BY-SA 3.0 (attribution, share-alike); every output carries the licence and ChEMBL release. ## 2. Minimal request Call `POST https://api.firecrawl.dev/v2/scrape` with `{ alexandria: { provider, capability, options } }`. For a batch, send `{ alexandria: [...] }` with up to 10 calls. ```json { "provider": "ebi-ac-uk", "capability": "molecules/drug_indications", "options": { "chembl_id": "CHEMBL941", "limit": 5 } } ``` ## 3. Add provider options Use only the options needed for the task: - `chembl_id` (string, required): Molecule ChEMBL ID (parent or salt), e.g. CHEMBL941. Pattern: ^CHEMBL[0-9]{1,12}$. Example: `` - `cursor` (string): next_cursor from the previous page of the same request. Pattern: ^[0-9]{1,8}$. Example: `` - `limit` (number): limit Example: `25` - `min_phase` (number): Only indications whose max_phase_for_ind is at least this (4 approved). Example: `0.5` ## 4. Request through your preferred interface ### JavaScript ```javascript const result = await firecrawl.scrape({ alexandria: { provider: "ebi-ac-uk", capability: "molecules/drug_indications", options: { chembl_id: "CHEMBL941", limit: 5, }, }, }); ``` ### Python ```python result = firecrawl.scrape_alexandria({ "provider": "ebi-ac-uk", "capability": "molecules/drug_indications", "options": { "chembl_id": "CHEMBL941", "limit": 5 } }) ``` ### cURL ```sh curl https://api.firecrawl.dev/v2/scrape \ -H "Authorization: Bearer $FIRECRAWL_API_KEY" \ -H "Content-Type: application/json" \ -d '{ "alexandria": { "provider": "ebi-ac-uk", "capability": "molecules/drug_indications", "options": { "chembl_id": "CHEMBL941", "limit": 5 } } }' ``` ### CLI ```sh firecrawl scrape 'ebi-ac-uk/molecules/drug_indications' \ --options '{"chembl_id":"CHEMBL941","limit":5}' ``` ### MCP Call the FCX MCP retrieve tool with this object: ```json { "provider": "ebi-ac-uk", "capability": "molecules/drug_indications", "options": { "chembl_id": "CHEMBL941", "limit": 5 } } ``` Ask for only the returned fields needed by the task. ## 5. Full request shape ```json { "provider": "ebi-ac-uk", "capability": "molecules/drug_indications", "options": { "chembl_id": "CHEMBL941", "limit": 5 } } ``` ## 6. Response data The response includes `success`, `provider`, `capability`, `creditsCost` and `data`. This example shows the provider payload in `data`: ```json { "attribution": { "citation": "Zdrazil B, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 2024;52(D1):D1180-D1192. doi:10.1093/nar/gkad1004", "license": "CC BY-SA 3.0", "license_url": "https://creativecommons.org/licenses/by-sa/3.0/", "release": "ChEMBL_37", "release_date": "2026-05-01", "source": "ChEMBL, EMBL-EBI", "source_url": "https://www.ebi.ac.uk/chembl/", "terms_url": "https://www.ebi.ac.uk/about/terms-of-use", "text": "Data from ChEMBL (ChEMBL_37), EMBL-EBI, https://www.ebi.ac.uk/chembl/, licensed under CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0/). Keep ChEMBL IDs and the release number when you reuse it; adaptations you distribute must carry the same licence." }, "indications": [ { "drugind_id": 23307, "efo_id": "EFO:0000339", "efo_term": "chronic myelogenous leukemia", "license": "CC BY-SA 3.0", "max_phase_for_ind": 4, "mesh_heading": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", "mesh_id": "D015464", "molecule_chembl_id": "CHEMBL1642", "parent_molecule_chembl_id": "CHEMBL941", "references": [ { "id": "NCT00015834,NCT00030394,NCT00038649,NCT00040105,NCT00047502,NCT00048672,NCT00049192,NCT00050531,NCT00054431,NCT00070499,NCT00081926,NCT00088231,NCT00101088,NCT00114959,NCT00124748,NCT00146913,NCT00171158,NCT00171223,NCT00171899,NCT00210119,NCT00219726,NCT00219739,NCT00219752,NCT00219765,NCT00390897,NCT00415909,NCT00511303,NCT00514488,NCT00594555,NCT00702403,NCT00845221,NCT01003054,NCT01221376,NCT01400074,NCT01578213,NCT01795716,NCT01827930,NCT02204644,NCT02687425,NCT02709083,NCT03241199,NCT04626024,NCT05623774", "type": "ClinicalTrials", "url": "https://clinicaltrials.gov/search?term=NCT00015834%20NCT00030394%20NCT00038649%20NCT00040105%20NCT00047502%20NCT00048672%20NCT00049192%20NCT00050531%20NCT00054431%20NCT00070499%20NCT00081926%20NCT00088231%20NCT00101088%20NCT00114959%20NCT00124748%20NCT00146913%20NCT00171158%20NCT00171223%20NCT00171899%20NCT00210119%20NCT00219726%20NCT00219739%20NCT00219752%20NCT00219765%20NCT00390897%20NCT00415909%20NCT00511303%20NCT00514488%20NCT00594555%20NCT00702403%20NCT00845221%20NCT01003054%20NCT01221376%20NCT01400074%20NCT01578213%20NCT01795716%20NCT01827930%20NCT02204644%20NCT02687425%20NCT02709083%20NCT03241199%20NCT04626024%20NCT05623774" }, { "id": "0e9927ab-771e-4c2d-881e-7031c40bf205", "type": "DailyMed", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e9927ab-771e-4c2d-881e-7031c40bf205" }, { "id": "211ef2da-2868-4a77-8055-1cb2cd78e24b", "type": "DailyMed", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" } ], "source_url": "https://www.ebi.ac.uk/chembl/api/data/drug_indication/23307.json" }, { "drugind_id": 24517, "efo_id": "EFO:0000220", "efo_term": "acute lymphoblastic leukemia", "license": "CC BY-SA 3.0", "max_phase_for_ind": 4, "mesh_heading": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "mesh_id": "D054198", "molecule_chembl_id": "CHEMBL1642", "parent_molecule_chembl_id": "CHEMBL941", "references": [ { "id": "NCT00154349,NCT00388895,NCT01222013,NCT01312818,NCT03023046", "type": "ClinicalTrials", "url": "https://clinicaltrials.gov/search?term=NCT00154349%20NCT00388895%20NCT01222013%20NCT01312818%20NCT03023046" } ], "source_url": "https://www.ebi.ac.uk/chembl/api/data/drug_indication/24517.json" }, { "drugind_id": 52060, "efo_id": "EFO:1001467", "efo_term": "Hypereosinophilic syndrome", "license": "CC BY-SA 3.0", "max_phase_for_ind": 4, "mesh_heading": "Hypereosinophilic Syndrome", "mesh_id": "D017681", "molecule_chembl_id": "CHEMBL1642", "parent_molecule_chembl_id": "CHEMBL941", "references": [ { "id": "NCT00171860,NCT00230334", "type": "ClinicalTrials", "url": "https://clinicaltrials.gov/search?term=NCT00171860%20NCT00230334" }, { "id": "EMEA/H/C/000406", "type": "EMA", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/glivec" } ], "source_url": "https://www.ebi.ac.uk/chembl/api/data/drug_indication/52060.json" }, { "drugind_id": 117423, "efo_id": "MONDO:0000870", "efo_term": "childhood acute lymphoblastic leukemia", "license": "CC BY-SA 3.0", "max_phase_for_ind": 4, "mesh_heading": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "mesh_id": "D054198", "molecule_chembl_id": "CHEMBL1642", "parent_molecule_chembl_id": "CHEMBL941", "references": [ { "id": "NCT00022737,NCT00702403", "type": "ClinicalTrials", "url": "https://clinicaltrials.gov/search?term=NCT00022737%20NCT00702403" } ], "source_url": "https://www.ebi.ac.uk/chembl/api/data/drug_indication/117423.json" }, { "drugind_id": 117424, "efo_id": "MONDO:0000873", "efo_term": "lymphoblastic lymphoma", "license": "CC BY-SA 3.0", "max_phase_for_ind": 4, "mesh_heading": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "mesh_id": "D054198", "molecule_chembl_id": "CHEMBL1642", "parent_molecule_chembl_id": "CHEMBL941", "references": [ { "id": "NCT03023046", "type": "ClinicalTrials", "url": "https://clinicaltrials.gov/search?term=NCT03023046" } ], "source_url": "https://www.ebi.ac.uk/chembl/api/data/drug_indication/117424.json" } ], "min_phase": null, "molecule_chembl_id": "CHEMBL941", "next_cursor": "5", "observed_at_ms": 1792445177264, "offset": 0, "parent_molecule_chembl_id": "CHEMBL941", "pref_name": "IMATINIB", "total_count": 134 } ``` ## API reference-derived contract The following capability contract is generated from the same normalized Alexandria API reference exposed in the API spec. ### Drug indications - Capability: `molecules/drug_indications` - Description: Drug indications ChEMBL records for a molecule and all forms of its parent compound: EFO and MeSH disease terms, the highest phase reached for each indication, and references (ClinicalTrials.gov, DailyMed, FDA, EMA, ATC). Most advanced phase first; min_phase 4 keeps approved indications. Paginated. Data CC BY-SA 3.0 with attribution. - Instructions: What a drug is approved or in trials for. Pass any form (parent or salt); the result covers the parent family. - Cost: 5 credits per call - Capability file: [Drug indications](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/molecules/drug_indications) Accepted options: - `chembl_id` (string, required): Molecule ChEMBL ID (parent or salt), e.g. CHEMBL941. Pattern: ^CHEMBL[0-9]{1,12}$. Example: `` - `cursor` (string): next_cursor from the previous page of the same request. Pattern: ^[0-9]{1,8}$. Example: `` - `limit` (number): limit Example: `25` - `min_phase` (number): Only indications whose max_phase_for_ind is at least this (4 approved). Example: `0.5` Response schema example: ```json { "attribution": { "citation": "Zdrazil B, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 2024;52(D1):D1180-D1192. doi:10.1093/nar/gkad1004", "license": "CC BY-SA 3.0", "license_url": "https://creativecommons.org/licenses/by-sa/3.0/", "release": "ChEMBL_37", "release_date": "2026-05-01", "source": "ChEMBL, EMBL-EBI", "source_url": "https://www.ebi.ac.uk/chembl/", "terms_url": "https://www.ebi.ac.uk/about/terms-of-use", "text": "Data from ChEMBL (ChEMBL_37), EMBL-EBI, https://www.ebi.ac.uk/chembl/, licensed under CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0/). Keep ChEMBL IDs and the release number when you reuse it; adaptations you distribute must carry the same licence." }, "indications": [ { "drugind_id": 23307, "efo_id": "EFO:0000339", "efo_term": "chronic myelogenous leukemia", "license": "CC BY-SA 3.0", "max_phase_for_ind": 4, "mesh_heading": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", "mesh_id": "D015464", "molecule_chembl_id": "CHEMBL1642", "parent_molecule_chembl_id": "CHEMBL941", "references": [ { "id": "NCT00015834,NCT00030394,NCT00038649,NCT00040105,NCT00047502,NCT00048672,NCT00049192,NCT00050531,NCT00054431,NCT00070499,NCT00081926,NCT00088231,NCT00101088,NCT00114959,NCT00124748,NCT00146913,NCT00171158,NCT00171223,NCT00171899,NCT00210119,NCT00219726,NCT00219739,NCT00219752,NCT00219765,NCT00390897,NCT00415909,NCT00511303,NCT00514488,NCT00594555,NCT00702403,NCT00845221,NCT01003054,NCT01221376,NCT01400074,NCT01578213,NCT01795716,NCT01827930,NCT02204644,NCT02687425,NCT02709083,NCT03241199,NCT04626024,NCT05623774", "type": "ClinicalTrials", "url": "https://clinicaltrials.gov/search?term=NCT00015834%20NCT00030394%20NCT00038649%20NCT00040105%20NCT00047502%20NCT00048672%20NCT00049192%20NCT00050531%20NCT00054431%20NCT00070499%20NCT00081926%20NCT00088231%20NCT00101088%20NCT00114959%20NCT00124748%20NCT00146913%20NCT00171158%20NCT00171223%20NCT00171899%20NCT00210119%20NCT00219726%20NCT00219739%20NCT00219752%20NCT00219765%20NCT00390897%20NCT00415909%20NCT00511303%20NCT00514488%20NCT00594555%20NCT00702403%20NCT00845221%20NCT01003054%20NCT01221376%20NCT01400074%20NCT01578213%20NCT01795716%20NCT01827930%20NCT02204644%20NCT02687425%20NCT02709083%20NCT03241199%20NCT04626024%20NCT05623774" }, { "id": "0e9927ab-771e-4c2d-881e-7031c40bf205", "type": "DailyMed", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e9927ab-771e-4c2d-881e-7031c40bf205" }, { "id": "211ef2da-2868-4a77-8055-1cb2cd78e24b", "type": "DailyMed", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b" } ], "source_url": "https://www.ebi.ac.uk/chembl/api/data/drug_indication/23307.json" }, { "drugind_id": 24517, "efo_id": "EFO:0000220", "efo_term": "acute lymphoblastic leukemia", "license": "CC BY-SA 3.0", "max_phase_for_ind": 4, "mesh_heading": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "mesh_id": "D054198", "molecule_chembl_id": "CHEMBL1642", "parent_molecule_chembl_id": "CHEMBL941", "references": [ { "id": "NCT00154349,NCT00388895,NCT01222013,NCT01312818,NCT03023046", "type": "ClinicalTrials", "url": "https://clinicaltrials.gov/search?term=NCT00154349%20NCT00388895%20NCT01222013%20NCT01312818%20NCT03023046" } ], "source_url": "https://www.ebi.ac.uk/chembl/api/data/drug_indication/24517.json" }, { "drugind_id": 52060, "efo_id": "EFO:1001467", "efo_term": "Hypereosinophilic syndrome", "license": "CC BY-SA 3.0", "max_phase_for_ind": 4, "mesh_heading": "Hypereosinophilic Syndrome", "mesh_id": "D017681", "molecule_chembl_id": "CHEMBL1642", "parent_molecule_chembl_id": "CHEMBL941", "references": [ { "id": "NCT00171860,NCT00230334", "type": "ClinicalTrials", "url": "https://clinicaltrials.gov/search?term=NCT00171860%20NCT00230334" }, { "id": "EMEA/H/C/000406", "type": "EMA", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/glivec" } ], "source_url": "https://www.ebi.ac.uk/chembl/api/data/drug_indication/52060.json" }, { "drugind_id": 117423, "efo_id": "MONDO:0000870", "efo_term": "childhood acute lymphoblastic leukemia", "license": "CC BY-SA 3.0", "max_phase_for_ind": 4, "mesh_heading": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "mesh_id": "D054198", "molecule_chembl_id": "CHEMBL1642", "parent_molecule_chembl_id": "CHEMBL941", "references": [ { "id": "NCT00022737,NCT00702403", "type": "ClinicalTrials", "url": "https://clinicaltrials.gov/search?term=NCT00022737%20NCT00702403" } ], "source_url": "https://www.ebi.ac.uk/chembl/api/data/drug_indication/117423.json" }, { "drugind_id": 117424, "efo_id": "MONDO:0000873", "efo_term": "lymphoblastic lymphoma", "license": "CC BY-SA 3.0", "max_phase_for_ind": 4, "mesh_heading": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "mesh_id": "D054198", "molecule_chembl_id": "CHEMBL1642", "parent_molecule_chembl_id": "CHEMBL941", "references": [ { "id": "NCT03023046", "type": "ClinicalTrials", "url": "https://clinicaltrials.gov/search?term=NCT03023046" } ], "source_url": "https://www.ebi.ac.uk/chembl/api/data/drug_indication/117424.json" } ], "min_phase": null, "molecule_chembl_id": "CHEMBL941", "next_cursor": "5", "observed_at_ms": 1792445177264, "offset": 0, "parent_molecule_chembl_id": "CHEMBL941", "pref_name": "IMATINIB", "total_count": 134 } ``` ### Get molecule - Capability: `molecules/get_molecule` - Description: One ChEMBL molecule by ChEMBL ID, standard InChIKey or ChEMBL compound URL: preferred name, type, max phase, first approval, availability, drug flags (oral, black box warning, first in class, ...), ATC codes, structure (canonical SMILES, InChI, InChIKey), calculated properties (MW, ALogP, PSA, HBA/HBD, rotatable bonds, Ro5 violations, QED), biotherapeutic sequence and HELM for antibodies and proteins, typed synonyms, cross-references, and the mechanisms of action of its parent compound with targets and references. Data CC BY-SA 3.0 with attribution; ChEMBL computes the properties with RDKit and ChemAxon software and asks that they not be extracted in isolation to train models that replicate the commercial calculations. - Instructions: Read a compound or drug once you have its ChEMBL ID (from search_molecules) or an InChIKey from another database. Mechanism target_chembl_id values feed get_target and list_activities. - Cost: 5 credits per call - Capability file: [Get molecule](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/molecules/get_molecule) Accepted options: - `chembl_id` (string): Molecule ChEMBL ID, e.g. CHEMBL941 (imatinib). Pattern: ^CHEMBL[0-9]{1,12}$. Example: `` - `inchi_key` (string): Standard InChIKey, e.g. KTUFNOKKBVMGRW-UHFFFAOYSA-N. Pattern: ^[A-Z]{14}-[A-Z]{10}-[A-Z]$. Example: `` - `url` (string): ChEMBL compound page, e.g. https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL941. Example: `` Response schema example: ```json { "active_chembl_id": "CHEMBL941", "atc_classifications": [ "L01EA01" ], "attribution": { "citation": "Zdrazil B, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 2024;52(D1):D1180-D1192. doi:10.1093/nar/gkad1004", "license": "CC BY-SA 3.0", "license_url": "https://creativecommons.org/licenses/by-sa/3.0/", "release": "ChEMBL_37", "release_date": "2026-05-01", "source": "ChEMBL, EMBL-EBI", "source_url": "https://www.ebi.ac.uk/chembl/", "terms_url": "https://www.ebi.ac.uk/about/terms-of-use", "text": "Data from ChEMBL (ChEMBL_37), EMBL-EBI, https://www.ebi.ac.uk/chembl/, licensed under CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0/). Keep ChEMBL IDs and the release number when you reuse it; adaptations you distribute must carry the same licence." }, "availability_type": "prescription_only", "biotherapeutic": null, "chirality": "achiral", "cross_references": [], "first_approval": 2001, "flags": { "black_box_warning": false, "chemical_probe": true, "first_in_class": false, "natural_product": true, "oral": true, "orphan": false, "parenteral": false, "prodrug": false, "therapeutic_flag": true, "topical": false, "veterinary": false, "withdrawn_flag": false }, "license": "CC BY-SA 3.0", "max_phase": 4, "mechanisms": [ { "action_type": "INHIBITOR", "binding_site_comment": null, "direct_interaction": true, "disease_efficacy": true, "max_phase": 4, "mechanism_comment": "Mechanism_for_indication: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive", "mechanism_of_action": "Tyrosine-protein kinase ABL inhibitor", "molecular_mechanism": true, "molecule_chembl_id": "CHEMBL1642", "references": [ { "id": "setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "type": "DailyMed", "url": "http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13" }, { "id": "Bcr-Abl_tyrosine-kinase_inhibitor", "type": "Wikipedia", "url": "http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor" } ], "selectivity_comment": null, "target_chembl_id": "CHEMBL1862" }, { "action_type": "INHIBITOR", "binding_site_comment": null, "direct_interaction": true, "disease_efficacy": true, "max_phase": 4, "mechanism_comment": "Mechanism_for_indication: Dermatofibrosarcoma, Hypereosinophilic Syndrome, Myelodysplastic-Myeloproliferative Diseases", "mechanism_of_action": "Platelet-derived growth factor receptor beta inhibitor", "molecular_mechanism": true, "molecule_chembl_id": "CHEMBL1642", "references": [ { "id": "setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "type": "DailyMed", "url": "http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13" }, { "id": "Bcr-Abl_tyrosine-kinase_inhibitor", "type": "Wikipedia", "url": "http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor" } ], "selectivity_comment": null, "target_chembl_id": "CHEMBL1913" }, { "action_type": "INHIBITOR", "binding_site_comment": null, "direct_interaction": true, "disease_efficacy": true, "max_phase": 4, "mechanism_comment": "Mechanism_for_indication: Gastrointestinal Stromal Tumors", "mechanism_of_action": "Stem cell growth factor receptor inhibitor", "molecular_mechanism": true, "molecule_chembl_id": "CHEMBL1642", "references": [ { "id": "setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13", "type": "DailyMed", "url": "http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b#section-13" }, { "id": "Bcr-Abl_tyrosine-kinase_inhibitor", "type": "Wikipedia", "url": "http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor" } ], "selectivity_comment": null, "target_chembl_id": "CHEMBL1936" }, { "action_type": "INHIBITOR", "binding_site_comment": null, "direct_interaction": true, "disease_efficacy": true, "max_phase": 4, "mechanism_comment": "Mechanism_for_indication: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive", "mechanism_of_action": "Bcr/Abl fusion protein inhibitor", "molecular_mechanism": true, "molecule_chembl_id": "CHEMBL1642", "references": [ { "id": "label/2008/021588s024lbl.pdf", "type": "FDA", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf" } ], "selectivity_comment": null, "target_chembl_id": "CHEMBL2096618" } ], "molecule_chembl_id": "CHEMBL941", "molecule_type": "Small molecule", "observed_at_ms": 1792445174680, "parent_chembl_id": "CHEMBL941", "pref_name": "IMATINIB", "properties": { "alogp": 4.59, "aromatic_rings": 4, "full_molformula": "C29H31N7O", "full_mwt": 493.62, "hba": 7, "hbd": 2, "heavy_atoms": 37, "mw_freebase": 493.62, "np_likeness_score": -1.8, "num_ro5_violations": 0, "psa": 86.28, "qed_weighted": 0.39, "ro3_pass": false, "rtb": 7 }, "source_url": "https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL941", "structure_type": "MOL", "structures": { "canonical_smiles": "Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1", "standard_inchi": "InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)", "standard_inchi_key": "KTUFNOKKBVMGRW-UHFFFAOYSA-N" }, "synonyms": [ { "synonym": "CGP057148B", "type": "PND" }, { "synonym": "CGP-57148B", "type": "PND" }, { "synonym": "Glamox", "type": "OTHER" }, { "synonym": "GLAMOX", "type": "PND" }, { "synonym": "GLEEVEC", "type": "PND" }, { "synonym": "GLEEVEC,STI-571", "type": "PND" }, { "synonym": "GLIVEC", "type": "PND" }, { "synonym": "Imatinib", "type": "ATC" }, { "synonym": "Imatinib", "type": "BAN" }, { "synonym": "Imatinib", "type": "INN" }, { "synonym": "Imatinib", "type": "MERCK_INDEX" }, { "synonym": "Imatinib", "type": "OTHER" }, { "synonym": "IMATINIB", "type": "PND" }, { "synonym": "IMATINIB MESYLATE", "type": "PND" }, { "synonym": "IMATINIB MESYLATEGLEEVECGLIVECIMATINIBSTI571CGP 571484-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]-PHENYL]BENZAMIDE", "type": "PND" }, { "synonym": "IMATINIB (STI571)", "type": "PND" }, { "synonym": "NSC-743414", "type": "PND" }, { "synonym": "NSC-743414", "type": "RESEARCH_CODE" }, { "synonym": "NSC-759854", "type": "PND" }, { "synonym": "NSC-759854", "type": "RESEARCH_CODE" }, { "synonym": "ST-1571", "type": "PND" }, { "synonym": "STI-571", "type": "PND" }, { "synonym": "STI571", "type": "PND" }, { "synonym": "STI571,GLEEVEC", "type": "PND" } ], "usan_stem": "-tinib", "usan_stem_definition": "tyrosine kinase inhibitors", "usan_year": null } ``` ### Search molecules - Capability: `molecules/search_molecules` - Description: Search ChEMBL molecules by name, synonym, trade name or research code (imatinib, Gleevec, STI571, aspirin), ranked by relevance. Each hit has the ChEMBL ID, preferred name, type, max development phase, first approval year, parent compound, canonical SMILES, standard InChIKey, formula, molecular weight and synonyms. Optional min_phase keeps clinical or approved drugs (4). Paginated; ChEMBL search stops at 10,000 hits. Data CC BY-SA 3.0 with attribution. - Instructions: Start here to turn a drug or compound name into a ChEMBL ID for get_molecule, drug_indications or list_activities. Salts are separate molecules (imatinib CHEMBL941, imatinib mesylate CHEMBL1642) sharing parent_chembl_id. - Cost: 5 credits per call - Capability file: [Search molecules](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/molecules/search_molecules) Accepted options: - `cursor` (string): next_cursor from the previous page of the same request. Pattern: ^[0-9]{1,8}$. Example: `` - `limit` (number): limit Example: `10` - `min_phase` (number): Only molecules whose max_phase is at least this: 4 approved, 3/2/1 clinical, 0.5 early phase 1. Example: `0.5` - `query` (string, required): Name, synonym, trade name or research code. Example: `` Response schema example: ```json { "attribution": { "citation": "Zdrazil B, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 2024;52(D1):D1180-D1192. doi:10.1093/nar/gkad1004", "license": "CC BY-SA 3.0", "license_url": "https://creativecommons.org/licenses/by-sa/3.0/", "release": "ChEMBL_37", "release_date": "2026-05-01", "source": "ChEMBL, EMBL-EBI", "source_url": "https://www.ebi.ac.uk/chembl/", "terms_url": "https://www.ebi.ac.uk/about/terms-of-use", "text": "Data from ChEMBL (ChEMBL_37), EMBL-EBI, https://www.ebi.ac.uk/chembl/, licensed under CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0/). Keep ChEMBL IDs and the release number when you reuse it; adaptations you distribute must carry the same licence." }, "min_phase": null, "next_cursor": null, "observed_at_ms": 1792445172207, "offset": 0, "query": "imatinib", "results": [ { "canonical_smiles": "Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1", "first_approval": 2001, "full_molformula": "C29H31N7O", "full_mwt": 493.62, "license": "CC BY-SA 3.0", "max_phase": 4, "molecule_chembl_id": "CHEMBL941", "molecule_type": "Small molecule", "parent_chembl_id": "CHEMBL941", "pref_name": "IMATINIB", "score": 36, "source_url": "https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL941", "standard_inchi_key": "KTUFNOKKBVMGRW-UHFFFAOYSA-N", "synonyms": [ "CGP057148B", "CGP-57148B", "Glamox", "GLAMOX", "GLEEVEC", "GLEEVEC,STI-571", "GLIVEC", "Imatinib", "IMATINIB", "IMATINIB MESYLATE", "IMATINIB MESYLATEGLEEVECGLIVECIMATINIBSTI571CGP 571484-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]-PHENYL]BENZAMIDE", "IMATINIB (STI571)", "NSC-743414", "NSC-759854", "ST-1571", "STI-571", "STI571", "STI571,GLEEVEC" ] }, { "canonical_smiles": "CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1", "first_approval": 2001, "full_molformula": "C30H35N7O4S", "full_mwt": 589.72, "license": "CC BY-SA 3.0", "max_phase": 4, "molecule_chembl_id": "CHEMBL1642", "molecule_type": "Small molecule", "parent_chembl_id": "CHEMBL941", "pref_name": "IMATINIB MESYLATE", "score": 36, "source_url": "https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1642", "standard_inchi_key": "YLMAHDNUQAMNNX-UHFFFAOYSA-N", "synonyms": [ "Gleevec", "Glivec", "Imatinib accord", "Imatinib actavis", "Imatinib (as mesilate)", "Imatinib koanaa", "Imatinib medac", "Imatinib mesilate", "Imatinib mesylate", "Imatinib methane sulfonate", "Imatinib methanesulfonate", "Imatinib teva", "Imatinib teva b.v.", "NSC-716051", "QTI-571", "Qti571", "QTI571", "STI 571", "STI-571", "STI571" ] }, { "canonical_smiles": "Cc1ccc(NC(=O)c2ccc(CN3CCNCC3)cc2)cc1Nc1nccc(-c2cccnc2)n1", "first_approval": null, "full_molformula": "C28H29N7O", "full_mwt": 479.59, "license": "CC BY-SA 3.0", "max_phase": null, "molecule_chembl_id": "CHEMBL3040018", "molecule_type": "Small molecule", "parent_chembl_id": "CHEMBL3040018", "pref_name": null, "score": 17, "source_url": "https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3040018", "standard_inchi_key": "BQQYXPHRXIZMDM-UHFFFAOYSA-N", "synonyms": [] }, { "canonical_smiles": "[2H]C([2H])([2H])N1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1", "first_approval": null, "full_molformula": "C29H31N7O", "full_mwt": 496.63, "license": "CC BY-SA 3.0", "max_phase": null, "molecule_chembl_id": "CHEMBL2386595", "molecule_type": "Small molecule", "parent_chembl_id": "CHEMBL941", "pref_name": null, "score": 16, "source_url": "https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2386595", "standard_inchi_key": "KTUFNOKKBVMGRW-BMSJAHLVSA-N", "synonyms": [] }, { "canonical_smiles": "CN1CCN(Cc2ccc(C(=O)Nc3cccc(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1", "first_approval": null, "full_molformula": "C28H29N7O", "full_mwt": 479.59, "license": "CC BY-SA 3.0", "max_phase": null, "molecule_chembl_id": "CHEMBL56904", "molecule_type": "Small molecule", "parent_chembl_id": "CHEMBL56904", "pref_name": null, "score": 9, "source_url": "https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL56904", "standard_inchi_key": "JHMBUEWQJDGKGS-UHFFFAOYSA-N", "synonyms": [] } ], "total_count": 5 } ``` ### Get target - Capability: `targets/get_target` - Description: One ChEMBL target by ChEMBL ID or ChEMBL target URL: name, type, organism, taxonomy ID and every component with its UniProt accession, gene symbol and synonyms (gene names, UniProt names, EC numbers); include_xrefs adds each component's PDB, Reactome, GO, InterPro, Pfam and other cross-references. Data CC BY-SA 3.0 with attribution. - Instructions: Read a target found through search_targets or a mechanism of action; then list_activities with its target_chembl_id for the compounds measured against it. - Cost: 5 credits per call - Capability file: [Get target](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/targets/get_target) Accepted options: - `chembl_id` (string): Target ChEMBL ID, e.g. CHEMBL203 (EGFR). Pattern: ^CHEMBL[0-9]{1,12}$. Example: `` - `include_xrefs` (boolean): Add component cross-references (hundreds for well-studied proteins). Example: `false` - `url` (string): ChEMBL target page, e.g. https://www.ebi.ac.uk/chembl/explore/target/CHEMBL203. Example: `` Response schema example: ```json { "attribution": { "citation": "Zdrazil B, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 2024;52(D1):D1180-D1192. doi:10.1093/nar/gkad1004", "license": "CC BY-SA 3.0", "license_url": "https://creativecommons.org/licenses/by-sa/3.0/", "release": "ChEMBL_37", "release_date": "2026-05-01", "source": "ChEMBL, EMBL-EBI", "source_url": "https://www.ebi.ac.uk/chembl/", "terms_url": "https://www.ebi.ac.uk/about/terms-of-use", "text": "Data from ChEMBL (ChEMBL_37), EMBL-EBI, https://www.ebi.ac.uk/chembl/, licensed under CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0/). Keep ChEMBL IDs and the release number when you reuse it; adaptations you distribute must carry the same licence." }, "components": [ { "accession": "P00533", "component_id": 147, "component_type": "PROTEIN", "description": "Epidermal growth factor receptor", "gene_symbol": "EGFR", "relationship": "SINGLE PROTEIN", "synonyms": [ { "synonym": "2.7.10.1", "type": "EC_NUMBER" }, { "synonym": "EGFR", "type": "GENE_SYMBOL" }, { "synonym": "Epidermal growth factor receptor", "type": "UNIPROT" }, { "synonym": "ERBB", "type": "GENE_SYMBOL_OTHER" }, { "synonym": "ERBB1", "type": "GENE_SYMBOL_OTHER" }, { "synonym": "HER1", "type": "GENE_SYMBOL_OTHER" }, { "synonym": "Proto-oncogene c-ErbB-1", "type": "UNIPROT" }, { "synonym": "Receptor tyrosine-protein kinase erbB-1", "type": "UNIPROT" } ], "xrefs": null } ], "cross_references": [], "license": "CC BY-SA 3.0", "observed_at_ms": 1792445182916, "organism": "Homo sapiens", "pref_name": "Epidermal growth factor receptor", "source_url": "https://www.ebi.ac.uk/chembl/explore/target/CHEMBL203", "species_group_flag": false, "target_chembl_id": "CHEMBL203", "target_type": "SINGLE PROTEIN", "tax_id": 9606 } ``` ### Search targets - Capability: `targets/search_targets` - Description: Find ChEMBL drug targets by free text (gene symbol, protein name, e.g. EGFR, cyclooxygenase) or by exact UniProt accession, optionally restricted to an organism (exact name, e.g. Homo sapiens) and target type (SINGLE PROTEIN, PROTEIN COMPLEX, ...). Each target has its ChEMBL ID, name, type, organism, taxonomy ID and components with UniProt accessions and gene symbols. Paginated. Data CC BY-SA 3.0 with attribution. - Instructions: Turn a gene, protein or UniProt accession into ChEMBL target IDs for get_target and list_activities. One protein usually maps to a SINGLE PROTEIN target plus complexes, families and protein-protein interaction targets that contain it. - Cost: 5 credits per call - Capability file: [Search targets](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/targets/search_targets) Accepted options: - `cursor` (string): next_cursor from the previous page of the same request. Pattern: ^[0-9]{1,8}$. Example: `` - `limit` (number): limit Example: `10` - `organism` (string): Exact organism name as ChEMBL stores it, case-sensitive, e.g. Homo sapiens. Example: `` - `query` (string): Gene symbol, protein or target name. Example: `` - `target_type` (string): ChEMBL target type, e.g. SINGLE PROTEIN, PROTEIN COMPLEX, PROTEIN FAMILY. Pattern: ^[A-Za-z][A-Za-z -]{1,40}$. Example: `` - `uniprot_accession` (string): UniProt accession, e.g. P00533 (EGFR); returns every target with that component. Pattern: ^([OPQ][0-9][A-Z0-9]{3}[0-9]|[A-NR-Z][0-9]([A-Z][A-Z0-9]{2}[0-9]){1,2})$. Example: `` Response schema example: ```json { "attribution": { "citation": "Zdrazil B, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 2024;52(D1):D1180-D1192. doi:10.1093/nar/gkad1004", "license": "CC BY-SA 3.0", "license_url": "https://creativecommons.org/licenses/by-sa/3.0/", "release": "ChEMBL_37", "release_date": "2026-05-01", "source": "ChEMBL, EMBL-EBI", "source_url": "https://www.ebi.ac.uk/chembl/", "terms_url": "https://www.ebi.ac.uk/about/terms-of-use", "text": "Data from ChEMBL (ChEMBL_37), EMBL-EBI, https://www.ebi.ac.uk/chembl/, licensed under CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0/). Keep ChEMBL IDs and the release number when you reuse it; adaptations you distribute must carry the same licence." }, "next_cursor": "5", "observed_at_ms": 1792445180434, "offset": 0, "organism": "Homo sapiens", "query": "EGFR", "results": [ { "components": [ { "accession": "P00533", "component_type": "PROTEIN", "description": "Epidermal growth factor receptor", "gene_symbol": "EGFR", "relationship": "INTERACTING PROTEIN" }, { "accession": "P62136", "component_type": "PROTEIN", "description": "Serine/threonine-protein phosphatase PP1-alpha catalytic subunit", "gene_symbol": "PPP1CA", "relationship": "INTERACTING PROTEIN" } ], "license": "CC BY-SA 3.0", "organism": "Homo sapiens", "pref_name": "EGFR/PPP1CA", "score": 17, "source_url": "https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4523747", "species_group_flag": false, "target_chembl_id": "CHEMBL4523747", "target_type": "PROTEIN-PROTEIN INTERACTION", "tax_id": 9606 }, { "components": [ { "accession": "P00533", "component_type": "PROTEIN", "description": "Epidermal growth factor receptor", "gene_symbol": "EGFR", "relationship": "INTERACTING PROTEIN" }, { "accession": "P29279", "component_type": "PROTEIN", "description": "CCN family member 2", "gene_symbol": "CCN2", "relationship": "INTERACTING PROTEIN" } ], "license": "CC BY-SA 3.0", "organism": "Homo sapiens", "pref_name": "CCN2-EGFR", "score": 17, "source_url": "https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5465557", "species_group_flag": false, "target_chembl_id": "CHEMBL5465557", "target_type": "PROTEIN-PROTEIN INTERACTION", "tax_id": 9606 }, { "components": [ { "accession": "P00533", "component_type": "PROTEIN", "description": "Epidermal growth factor receptor", "gene_symbol": "EGFR", "relationship": "SINGLE PROTEIN" } ], "license": "CC BY-SA 3.0", "organism": "Homo sapiens", "pref_name": "Epidermal growth factor receptor", "score": 11, "source_url": "https://www.ebi.ac.uk/chembl/explore/target/CHEMBL203", "species_group_flag": false, "target_chembl_id": "CHEMBL203", "target_type": "SINGLE PROTEIN", "tax_id": 9606 }, { "components": [ { "accession": "P00533", "component_type": "PROTEIN", "description": "Epidermal growth factor receptor", "gene_symbol": "EGFR", "relationship": "INTERACTING PROTEIN" }, { "accession": "Q96SW2", "component_type": "PROTEIN", "description": "Protein cereblon", "gene_symbol": "CRBN", "relationship": "INTERACTING PROTEIN" } ], "license": "CC BY-SA 3.0", "organism": "Homo sapiens", "pref_name": "Protein cereblon/Epidermal growth factor receptor", "score": 11, "source_url": "https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4523680", "species_group_flag": false, "target_chembl_id": "CHEMBL4523680", "target_type": "PROTEIN-PROTEIN INTERACTION", "tax_id": 9606 }, { "components": [ { "accession": "P04626", "component_type": "PROTEIN", "description": "Receptor tyrosine-protein kinase erbB-2", "gene_symbol": "ERBB2", "relationship": "GROUP MEMBER" }, { "accession": "P00533", "component_type": "PROTEIN", "description": "Epidermal growth factor receptor", "gene_symbol": "EGFR", "relationship": "GROUP MEMBER" }, { "accession": "Q15303", "component_type": "PROTEIN", "description": "Receptor tyrosine-protein kinase erbB-4", "gene_symbol": "ERBB4", "relationship": "GROUP MEMBER" }, { "accession": "P21860", "component_type": "PROTEIN", "description": "Receptor tyrosine-protein kinase erbB-3", "gene_symbol": "ERBB3", "relationship": "GROUP MEMBER" } ], "license": "CC BY-SA 3.0", "organism": "Homo sapiens", "pref_name": "Epidermal growth factor receptor", "score": 10, "source_url": "https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2363049", "species_group_flag": false, "target_chembl_id": "CHEMBL2363049", "target_type": "PROTEIN FAMILY", "tax_id": 9606 } ], "target_type": null, "total_count": 21, "uniprot_accession": null } ``` ### List activities - Capability: `activities/list_activities` - Description: Bioactivity measurements from ChEMBL for a molecule, a parent compound with all its salt forms, a target, or a molecule-target pair: standard type (IC50, Ki, Kd, EC50, ...), relation, value and units, pChEMBL value, assay (ChEMBL ID, type, description, variant mutation), target, ligand efficiency, data-validity flags and source document. Filters: standard_type, min_pchembl, assay_type, target_organism. sort potency returns the most potent first (rows with a pChEMBL value only). Paginated. Data CC BY-SA 3.0 with attribution. - Instructions: Potency and SAR data: how strongly a compound hits a target, or which compounds are most potent against a target. Get IDs from search_molecules / search_targets first. - Cost: 5 credits per call - Capability file: [List activities](https://firecrawl.dev/alexandria/agents/providers/ebi-ac-uk/activities/list_activities) Accepted options: - `assay_type` (string): B binding, F functional, A ADME, T toxicity, P physicochemical, U unclassified. Example: `B` - `cursor` (string): next_cursor from the previous page of the same request. Pattern: ^[0-9]{1,8}$. Example: `` - `limit` (number): limit Example: `20` - `min_pchembl` (number): Only rows with pchembl_value at least this (6 = 1 uM, 9 = 1 nM). Example: `10` - `molecule_chembl_id` (string): Measurements recorded on exactly this molecule form. Pattern: ^CHEMBL[0-9]{1,12}$. Example: `` - `parent_molecule_chembl_id` (string): Measurements on a parent compound and all its salts and forms (parent_chembl_id from get_molecule). Pattern: ^CHEMBL[0-9]{1,12}$. Example: `` - `sort` (string): activity_id (stable record order) or potency (highest pChEMBL first; rows without one are excluded). Example: `activity_id` - `standard_type` (string): Endpoint, e.g. IC50, Ki, Kd, EC50, Potency, Inhibition (common ones are case-insensitive). Pattern: ^[A-Za-z0-9][A-Za-z0-9 ()%/._+'-]{0,39}$. Example: `` - `target_chembl_id` (string): Target ChEMBL ID, e.g. CHEMBL203. Pattern: ^CHEMBL[0-9]{1,12}$. Example: `` - `target_organism` (string): Exact target organism, case-sensitive, e.g. Homo sapiens. Example: `` Response schema example: ```json { "activities": [ { "activity_comment": null, "activity_id": 909963, "assay_chembl_id": "CHEMBL846547", "assay_description": "Inhibition of v-Abl tyrosine kinase.", "assay_type": "B", "assay_variant_accession": null, "assay_variant_mutation": null, "bao_label": "single protein format", "canonical_smiles": "Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1", "data_validity_comment": null, "document_chembl_id": "CHEMBL1130562", "document_journal": "Bioorg Med Chem Lett", "document_year": 1997, "license": "CC BY-SA 3.0", "ligand_efficiency": { "bei": 15.03, "le": 0.27, "lle": 2.83, "sei": 8.6 }, "molecule_chembl_id": "CHEMBL941", "molecule_pref_name": "IMATINIB", "parent_molecule_chembl_id": "CHEMBL941", "pchembl_value": 7.42, "potential_duplicate": false, "source_url": "https://www.ebi.ac.uk/chembl/api/data/activity/909963.json", "standard_relation": "=", "standard_text_value": null, "standard_type": "IC50", "standard_units": "nM", "standard_value": 38, "target_chembl_id": "CHEMBL1862", "target_organism": "Homo sapiens", "target_pref_name": "Tyrosine-protein kinase ABL1", "target_tax_id": 9606 }, { "activity_comment": null, "activity_id": 1614497, "assay_chembl_id": "CHEMBL882911", "assay_description": "Inhibitory concentration against v-Abl tyrosine kinase", "assay_type": "B", "assay_variant_accession": null, "assay_variant_mutation": null, "bao_label": "single protein format", "canonical_smiles": "Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1", "data_validity_comment": null, "document_chembl_id": "CHEMBL1140446", "document_journal": "J Med Chem", "document_year": 2005, "license": "CC BY-SA 3.0", "ligand_efficiency": { "bei": 15.03, "le": 0.27, "lle": 2.83, "sei": 8.6 }, "molecule_chembl_id": "CHEMBL941", "molecule_pref_name": "IMATINIB", "parent_molecule_chembl_id": "CHEMBL941", "pchembl_value": 7.42, "potential_duplicate": true, "source_url": "https://www.ebi.ac.uk/chembl/api/data/activity/1614497.json", "standard_relation": "=", "standard_text_value": null, "standard_type": "IC50", "standard_units": "nM", "standard_value": 38, "target_chembl_id": "CHEMBL1862", "target_organism": "Homo sapiens", "target_pref_name": "Tyrosine-protein kinase ABL1", "target_tax_id": 9606 }, { "activity_comment": null, "activity_id": 1907590, "assay_chembl_id": "CHEMBL888888", "assay_description": "Inhibition of c-Abl", "assay_type": "B", "assay_variant_accession": null, "assay_variant_mutation": null, "bao_label": "single protein format", "canonical_smiles": "Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1", "data_validity_comment": null, "document_chembl_id": "CHEMBL1145434", "document_journal": "Bioorg Med Chem Lett", "document_year": 2007, "license": "CC BY-SA 3.0", "ligand_efficiency": { "bei": 14.99, "le": 0.27, "lle": 2.81, "sei": 8.57 }, "molecule_chembl_id": "CHEMBL941", "molecule_pref_name": "IMATINIB", "parent_molecule_chembl_id": "CHEMBL941", "pchembl_value": 7.4, "potential_duplicate": false, "source_url": "https://www.ebi.ac.uk/chembl/api/data/activity/1907590.json", "standard_relation": "=", "standard_text_value": null, "standard_type": "IC50", "standard_units": "nM", "standard_value": 40, "target_chembl_id": "CHEMBL1862", "target_organism": "Homo sapiens", "target_pref_name": "Tyrosine-protein kinase ABL1", "target_tax_id": 9606 }, { "activity_comment": null, "activity_id": 1944620, "assay_chembl_id": "CHEMBL892514", "assay_description": "Inhibition of human Abl kinase expressed in Sf9 cells", "assay_type": "B", "assay_variant_accession": null, "assay_variant_mutation": null, "bao_label": "cell-based format", "canonical_smiles": "Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1", "data_validity_comment": null, "document_chembl_id": "CHEMBL1147914", "document_journal": "Bioorg Med Chem Lett", "document_year": 2007, "license": "CC BY-SA 3.0", "ligand_efficiency": { "bei": 12.82, "le": 0.23, "lle": 1.74, "sei": 7.33 }, "molecule_chembl_id": "CHEMBL941", "molecule_pref_name": "IMATINIB", "parent_molecule_chembl_id": "CHEMBL941", "pchembl_value": 6.33, "potential_duplicate": false, "source_url": "https://www.ebi.ac.uk/chembl/api/data/activity/1944620.json", "standard_relation": "=", "standard_text_value": null, "standard_type": "IC50", "standard_units": "nM", "standard_value": 470, "target_chembl_id": "CHEMBL1862", "target_organism": "Homo sapiens", "target_pref_name": "Tyrosine-protein kinase ABL1", "target_tax_id": 9606 }, { "activity_comment": null, "activity_id": 2280412, "assay_chembl_id": "CHEMBL1022422", "assay_description": "Inhibition of wild-type c-Abl by liquid scintillation counting", "assay_type": "B", "assay_variant_accession": null, "assay_variant_mutation": null, "bao_label": "single protein format", "canonical_smiles": "Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1", "data_validity_comment": null, "document_chembl_id": "CHEMBL1153406", "document_journal": "J Med Chem", "document_year": 2009, "license": "CC BY-SA 3.0", "ligand_efficiency": { "bei": 12.07, "le": 0.22, "lle": 1.37, "sei": 6.91 }, "molecule_chembl_id": "CHEMBL941", "molecule_pref_name": "IMATINIB", "parent_molecule_chembl_id": "CHEMBL941", "pchembl_value": 5.96, "potential_duplicate": false, "source_url": "https://www.ebi.ac.uk/chembl/api/data/activity/2280412.json", "standard_relation": "=", "standard_text_value": null, "standard_type": "IC50", "standard_units": "nM", "standard_value": 1100, "target_chembl_id": "CHEMBL1862", "target_organism": "Homo sapiens", "target_pref_name": "Tyrosine-protein kinase ABL1", "target_tax_id": 9606 } ], "attribution": { "citation": "Zdrazil B, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 2024;52(D1):D1180-D1192. doi:10.1093/nar/gkad1004", "license": "CC BY-SA 3.0", "license_url": "https://creativecommons.org/licenses/by-sa/3.0/", "release": "ChEMBL_37", "release_date": "2026-05-01", "source": "ChEMBL, EMBL-EBI", "source_url": "https://www.ebi.ac.uk/chembl/", "terms_url": "https://www.ebi.ac.uk/about/terms-of-use", "text": "Data from ChEMBL (ChEMBL_37), EMBL-EBI, https://www.ebi.ac.uk/chembl/, licensed under CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0/). Keep ChEMBL IDs and the release number when you reuse it; adaptations you distribute must carry the same licence." }, "filters": { "assay_type": null, "min_pchembl": null, "molecule_chembl_id": "CHEMBL941", "parent_molecule_chembl_id": null, "sort": "activity_id", "standard_type": "IC50", "target_chembl_id": "CHEMBL1862", "target_organism": null }, "next_cursor": "5", "observed_at_ms": 1792445185404, "offset": 0, "total_count": 94 } ```